Targeting the homing of stem cells via suppression of cell adhesion in the peripheral vasculature

The general approach of the so far developed technologies is the attempt to increase the homing rate of transplanted stem cells by modifying the molecules/receptors that interact directly with the chemokines/ligands in the damaged tissue. Our unique technology does not interact with the natural repertoire of specific molecules/receptors mediating homing of stem cells to the damaged tissue (SPECIFIC HOMING) but impairs the function of molecules/receptors that are responsible for the adhesion of stem cells throughout the non-damaged vasculature (NON-SPECIFIC CELL ADHESION). Moreover and most importantly, our highly effective technology is non-toxic, does not affect stem cell function and does not require genetic modifications thus making it a most promising candidate for clinical use